Official Journal of the Italian Society of Orthopaedics and Traumatology
Table 2 Outcomes at 26 weeks
PRP | HA | NSAID | P | |
|---|---|---|---|---|
Patients | 33 | 32 | 33 | |
Responders [no. (%)] | ||||
20% decrease WOMAC pain | 16 (48) | 7 (21) | 5 (15) | < 0.001 |
20% decrease WOMAC stiffness | 15 (45) | 5 (15) | 4 (12) | < 0.002 |
20% decrease WOMAC physical function | 15 (45) | 5 (15) | 4 (12) | < 0.05 |
20% decrease VAS | 16 (48) | 8 (25) | 6 (18) | < 0.021 |
Change from baseline | ||||
WOMAC pain | ||||
% change from baseline | − 22.38 | − 14.5 | − 5.9 | < 0.001 |
End of follow-up | 4.72 ± 0.87 | 5.15 ± 0.84 | 5.75 ± 0.43 | < 0.005 |
WOMAC stiffness | ||||
% change from baseline | − 18.3 | − 0.5 | 2.9 | < 0.05 |
End of follow-up | 3.36 ± 0.5 | 3.56 ± 0.5 | 4.18 ± 0.39 | < 0.001 |
WOMAC physical function | ||||
% change from baseline | − 21.1 | − 12 | 0.6 | < 0.001 |
End of follow-up | ± 0.6 | 28.62 ± 0.9 | 32.69 ± 0.8 | < 0.001 |
WOMAC total | ||||
% change from baseline | − 21.06 | − 12,39 | − 0.06 | < 0.03 |
End of follow-up | 33.6 ± 1.2 | 37.34 ± 1.2 | 42.63 ± 1.02 | < 0.002 |
VAS | ||||
% change from baseline | − 20.2 | − 13.92 | − 5.4 | < 0.001 |
End of follow-up | 4.9 ± 0.52 | 5.21 ± 0.6 | 5.81 ± 0.39 | < 0.001 |